A Dark Vector Cognition product

Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

2K characters. Original on sec.gov · Markdown

Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

| --- | --- |

(a)Our common stock is listed under the ticker symbol “AVY” on the New York Stock Exchange. We did not sell securities in any unregistered transactions during the fourth quarter of 2021.

We had 3,952 shareholders of record as of January 1, 2022, the last day of our fiscal year 2021.

The disclosure in our 2021 Annual Report under “Stockholder Return Performance” is incorporated herein by reference.

(b)Not applicable.
(c)Repurchases of Equity Securities by Issuer

Repurchases by us or our “affiliated purchasers” (as defined in Rule

10b-18(a)(3)

of the Exchange Act) of registered equity securities in the fourth quarter of 2021 are shown in the table below. Repurchased shares may be reissued under our long-term incentive plan or used for other corporate purposes.

Period (1)Total number of shares purchased (2)Average price paid per shareTotal number of shares purchased as part of publicly announced plans (2)(3)Approximate dollar value of shares that may yet be purchased under the plans (4)
October 3, 2021 – October 30, 202144.3$208.6244.3$405.3
October 31, 2021 – November 27, 202125.6218.7725.6399.7
November 28, 2021 – January 1, 2022192.0208.76192.0359.6
Total261.9$209.71261.9$359.6
(1)The periods shown are our fiscal periods during the thirteen-week quarter ended January 1, 2022.
(2)Shares in thousands.
(3)In April 2019, our Board authorized the repurchase of shares of our common stock with a fair market value of up to $650 million, excluding any fees, commissions or other expenses related to such purchases. This Board authorization will remain in effect until shares in the amount authorized thereunder have been repurchased.
(4)Dollars in millions.

Previous: Item 4. MINE SAFETY DISCLOSURES · Next: Item 6. RESERVED